Cargando…
Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625
BACKGROUND: Progressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in T1 non-progressors. We aimed to determin...
Autores principales: | Boxerman, Jerrold L., Snyder, Bradley S., Barboriak, Daniel P., Schmainda, Kathleen M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909012/ https://www.ncbi.nlm.nih.gov/pubmed/36776298 http://dx.doi.org/10.3389/fonc.2023.1061502 |
Ejemplares similares
-
Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: A multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma
por: ELLINGSON, BENJAMIN M., et al.
Publicado: (2015) -
Increased rCBV in status epilepticus
por: Rath, J. J. G., et al.
Publicado: (2012) -
Effect of Applying Leakage Correction on rCBV Measurement Derived From DSC-MRI in Enhancing and Nonenhancing Glioma
por: Arzanforoosh, Fatemeh, et al.
Publicado: (2021) -
Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO)
por: Bell, Laura C., et al.
Publicado: (2019) -
Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge
por: Bell, Laura C., et al.
Publicado: (2020)